In a filing, Vor Biopharma Inc revealed its CHIEF MEDICAL OFFICER Attar Eyal C. unloaded Company’s shares for reported $3162.0 on Feb 13 ’25. In the deal valued at $1.42 per share,2,227 shares were sold. As a result of this transaction, Attar Eyal C. now holds 126,625 shares worth roughly $0.11 million.
Then, EYAL ATTAR bought 2,227 shares, generating $3,073 in total proceeds.
Before that, Attar Eyal C. sold 2,554 shares. Vor Biopharma Inc shares valued at $3,499 were divested by the CHIEF MEDICAL OFFICER at a price of $1.37 per share. As a result of the transaction, Attar Eyal C. now holds 128,852 shares, worth roughly $0.11 million.
Wedbush initiated its Vor Biopharma Inc [VOR] rating to an Outperform in a research note published on July 26, 2022; the price target was $18. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late April with a ‘”a Neutral”‘ rating. H.C. Wainwright began covering VOR with “Buy” recommendation on December 17, 2021. Robert W. Baird started covering the stock on December 03, 2021. It rated VOR as “an Outperform”.
Price Performance Review of VOR
On Tuesday, Vor Biopharma Inc [NASDAQ:VOR] saw its stock fall -7.55% to $0.88. Over the last five days, the stock has lost -30.15%. Vor Biopharma Inc shares have fallen nearly -20.71% since the year began. Nevertheless, the stocks have fallen -61.73% over the past one year. While a 52-week high of $2.43 was reached on 01/06/25, a 52-week low of $0.63 was recorded on 03/04/25. SMA at 50 days reached $1.2905, while 200 days put it at $1.0482.
Levels Of Support And Resistance For VOR Stock
The 24-hour chart illustrates a support level at 0.8407, which if violated will result in even more drops to 0.8013. On the upside, there is a resistance level at 0.9388. A further resistance level may holdings at 0.9975. The Relative Strength Index (RSI) on the 14-day chart is 25.89, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.2807, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.86%. Stochastics %K at 12.88% indicates the stock is a buying.
The most recent change occurred on December 02, 2021 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
